Annual results and Q4 2025
Wednesday, February 04, 2026

Press release: English (PDF 0.4 MB) | Deutsch (PDF 0.4 MB)

Condensed financial report (PDF 0.5 MB)


Watch the webcast

Download the presentation (PDF 4.7 MB)

Download the podcast (MP3 35 MB)
 

Key figures1Q4 2025
(USD m2)
Q4 2024
(USD m2)
% change
(USD/cc)
Net sales13,33613,1531 (cc: -1)
Operating income3,6163,5302 (cc: 4)
Net income2,4042,820-15 (cc: -14)
EPS (USD)1.261.42-11 (cc: -11)
Free cash flow1,6553,635-54

Core
   
Operating income4,9294,8591 (cc: 1)
Net income3,8893,933-1 (cc: -2)
EPS (USD)2.031.983 (cc: 2)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 44 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
  2. USD millions unless indicated otherwise

Q3 2025 results - Tuesday, October 28, 2025

Press release: English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB)

Interim financial report (PDF 0.4 MB)


Quarterly impact and sustainability update (ESG):
Novartis Q3 2025 impact and sustainability update (PDF 0.8 MB)


Watch the webcast

Download the interactive presentation (PDF 5.6 MB)

Download the podcast (MP3 31 MB)
 

Key figures1Q3 2025
(USD m)
Q3 2024
(USD m)
% change
(USD/cc)
Net sales13,90912,8238 (cc: 7)
Operating income4,5013,62724 (cc: 27)
Net income3,9303,18523 (cc: 25)
EPS (USD)2.041.5829 (cc: 31)
Free cash flow6,2175,9654

Core
   
Operating income5,4605,1456 (cc: 7)
Net income4,3304,1335 (cc: 6)
EPS (USD)2.252.069 (cc: 10)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 42 of the Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

 

Q2 2025 results - Thursday, July 17, 2025

Press release: English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB)

Interim financial report (PDF 0.4 MB)


Quarterly impact and sustainability update (ESG):
Novartis Q2 2025 impact and sustainability update (PDF 0.8 MB)


Watch the webcast

Download the interactive presentation (PDF 4.6 MB)

Download the podcast (MP3 31 MB)

 

Key figures1Q2 2025
(USD m)
Q2 2024
(USD m)
% change
(USD/cc)
Net sales14,05412,51212 (cc: 11)
Operating income4,8644,01421 (cc: 25)
Net income4,0243,24624 (cc: 26)
EPS (USD)2.071.6029 (cc: 32)
Free cash flow6,3334,61537

Core
   
Operating income5,9254,95320 (cc: 21)
Net income4,7104,00818 (cc: 19)
EPS (USD)2.421.9723 (cc: 24)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 40 of the Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

Q1 2025 results - Tuesday, April 29, 2025

Press release: English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB)

Interim financial report (PDF 0.3 MB)


Quarterly impact and sustainability update (ESG):
Novartis Q1 2025 impact and sustainability update (PDF 0.9 MB)


Watch the webcast

Download the interactive presentation (PDF 3.7 MB)

Download the podcast (MP3 32 MB)

Download 2025 epidemiology data (PDF 2.0 MB)
 

Key figures1Q1 2025
(USD m)
Q1 2024
(USD m)
% change
(USD/cc)
Net sales13,23311,82912 (cc: 15)
Operating income4,6633,37338 (cc: 44)
Net income3,6092,68834 (cc: 37)
EPS (USD)1.831.3140 (cc: 42)
Free cash flow3,3912,03866

Core
   
Operating income5,5754,53723 (cc: 27)
Net income4,4823,68122 (cc: 26)
EPS (USD)2.281.8027 (cc: 31)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 31 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

 

2024 quarterly results

Q4 2024 press release (PDF 0.4 MB)

Q4 2024 financial report (PDF 0.5 MB)

Q3 2024 press release (PDF 0.4 MB)

Q3 2024 financial report (PDF 0.6 MB)

Q2 2024 press release (PDF 0.5 MB)

Q2 2024 financial report (PDF 0.5 MB)

Q1 2024 press release (PDF 0.4 MB)

Q1 2024 financial report (PDF 0.5 MB)

2023 quarterly results

Q4 2023 press release (PDF 0.3 MB)

Q4 2023 financial report (PDF 0.6 MB)

Q3 2023 press release (PDF 0.4 MB)

Q3 2023 financial report (PDF 0.6 MB)

Q2 2023 press release (PDF 0.3 MB)

Q2 2023 financial report (PDF 0.5 MB)

Q1 2023 press release (PDF 0.3 MB)

Q1 2023 financial report (PDF 0.3 MB)

2022 quarterly results

Q4 2022 press release (PDF 0.3 MB)

Q4 2022 financial report (PDF 0.5 MB)

Q3 2022 press release (PDF 0.3 MB)

Q3 2022 financial report (PDF 0.5 MB)

Q2 2022 press release (PDF 0.2 MB)

Q2 2022 financial report (PDF 0.5 MB)

Q1 2022 press release (PDF 0.2 MB)

Q1 2022 financial report (PDF 0.4 MB)

2021 quarterly results

Q4 2021 press release (PDF 0.3 MB)

Q4 2021 financial report (PDF 0.5 MB)

Reconciliation of 2021 results excluding Roche investment impacts (PDF 0.5 MB)

Q3 2021 press release (PDF 0.3 MB)

Q3 2021 financial report (PDF 0.5 MB)

Q2 2021 press release (PDF 0.4 MB)

Q2 2021 financial report (PDF 0.5 MB)

Q1 2021 press release (PDF 0.2 MB)

Q1 2021 financial report (PDF 0.4 MB)

2020 quarterly results

Q4 2020 press release (PDF 0.2 MB)

Q4 2020 financial report (PDF 0.9 MB)

Q3 2020 press release (PDF 0.2 MB)

Q3 2020 financial report (PDF 0.8 MB)

Q2 2020 press release (PDF 0.1 MB)

Q2 2020 financial report (PDF 0.8 MB)

Q1 2020 press release (PDF 0.2 MB)

Q1 2020 financial report (PDF 0.6 MB)